Literature DB >> 23386284

Irbesartan-mediated AT1 receptor blockade attenuates hyposmotic-induced enhancement of I Ks current and prevents shortening of action potential duration in atrial myocytes.

Jie Wu1, Wei-Guang Ding2, Jin Zhao3, Wei-Jin Zang3, Hiroshi Matsuura2, Minoru Horie4.   

Abstract

INTRODUCTION: Stretch of the atrial membrane upregulates the slow component of delayed rectifier K(+) current (I(Ks)). Blockade of angiotensin II subtype 1 receptors (AT(1)R) attenuates this increase in I(Ks). The present study aimed to examine the effects of irbesartan, a selective AT(1)R blocker (ABR), on both the enhancement of I(Ks) and the shortening of action potential duration (APD) induced by stretching atrial myocytes for exploring the mechanisms underlying the prevention of atrial fibrillation (AF) by ABR.
METHODS: Hyposmotic solution (Hypo-S) was used to stretch guinea pig atrial myocytes. I(Ks) and APD were recorded using the whole-cell patch-clamp technique.
RESULTS: Irbesartan (1-50 μM) attenuated the Hypo-S-induced increase in I(Ks) and shortening of APD90. Hypo-S increased the I(Ks) by 113.4%, whereas Hypo-S + 1 μM irbesartan and Hypo-S + 50 μM irbesartan increased the I(Ks) by only 74.5% and 70.3%, respectively. In addition, Hypo-S shortened the APD(90) by 19.0%, whereas Hypo-S + 1 μM irbesartan and Hypo-S + 50 μM irbesartan shortened the APD90 by 12.1% and 12.0%, respectively.
CONCLUSION: The actions of irbesartan on electrical changes induced by stretching atrial myocytes are associated with blocking AT(1)R. These actions may be beneficial for treating AF.
© The Author(s) 2013.

Entities:  

Keywords:  Angiotensin II type 1 receptor; Izzm321990 Ks; action potential; atrial myocytes; irbesartan

Mesh:

Substances:

Year:  2013        PMID: 23386284     DOI: 10.1177/1470320312474855

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  3 in total

Review 1.  Uremic Toxins - Novel Arrhythmogenic Factor in Chronic Kidney Disease - Related Atrial Fibrillation.

Authors:  Shih-Yu Huang; Yi-Ann Chen; Shih-Ann Chen; Yi-Jen Chen; Yung-Kuo Lin
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

2.  Irbesartan prevents sodium channel remodeling in a canine model of atrial fibrillation.

Authors:  Xuewen Wang; Guangping Li
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jan-Mar       Impact factor: 1.636

Review 3.  Anti-arrhythmic properties of non-antiarrhythmic medications.

Authors:  Emmanuel Ato Williams; Vincenzo Russo; Sergio Ceraso; Dhiraj Gupta; Richard Barrett-Jolley
Journal:  Pharmacol Res       Date:  2020-03-23       Impact factor: 7.658

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.